Related Experiment Video
Updated: Jul 14, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Small interfering RNA against PTTG: a novel therapy for ovarian cancer
Shahenda M El-Naggar1, Mohammed T Malik, Sham S Kakar
1Department of Medicine, and the James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.
Abstract:
Ovarian epithelial cancer is a significant cause of death among women, accounting for 5% of all female cancer-related fatalities. A lack of reliable detection methods and resistance to chemotherapy agents are considerable obstacles in the treatment of this cancer. Recently, high-level expression of the pituitary tumor transforming gene (PTTG) was found in a wide range of tumors, including ovarian cancers. Elevated PTTG levels were found to induce cellular transformation in vitro and tumor formation in nude mice. Therefore, we hypothesize a correlation exists between the levels of PTTG expression and tumorigenesis, and that down-regulation of PTTG levels will result in the suppression of tumor growth. We used small interfering RNA (siRNA) to silence PTTG expression in human A2780 ovarian carcinoma cells and assessed the effect of PTTG silencing in tumor formation in vitro and in vivo. The siRNA directed against PTTG reduced its expression at both the mRNA and protein levels. A fifty percent reduction in cell proliferation was achieved in cells constitutively expressing PTTG siRNA compared to vector or control-siRNA transfected cells. Furthermore, colony formation in soft agar was reduced by 70% in PTTG siRNA stable cell lines. Using nude mice, we showed that animals injected with A2780 cells constitutively expressing PTTG-siRNA decreased the incidence of tumor development and tumor growth. Taken together, these results strongly suggest that PTTG may serve as an important molecular target for the discovery of new anticancer agents and treatment strategies.
Insights
Silencing the pituitary tumor transforming gene (PTTG) with siRNA reduced ovarian cancer cell proliferation and tumor growth in mice. These findings highlight PTTG as a potential target for new ovarian cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ovarian epithelial cancer is a leading cause of female cancer deaths, with limited detection methods and chemotherapy resistance posing significant challenges.
- High expression of the pituitary tumor transforming gene (PTTG) is observed in various tumors, including ovarian cancer, and is linked to cellular transformation and tumor formation.
Purpose of the Study:
- To investigate the correlation between PTTG expression levels and ovarian tumorigenesis.
- To determine if down-regulating PTTG can suppress tumor growth in ovarian cancer models.
Main Methods:
- Small interfering RNA (siRNA) was used to silence PTTG expression in human A2780 ovarian carcinoma cells.
- The effects of PTTG silencing on cell proliferation, colony formation in soft agar, and tumor development in nude mice were assessed.
Main Results:
- PTTG siRNA effectively reduced PTTG expression at both mRNA and protein levels.
- A 50% reduction in cell proliferation and a 70% decrease in soft agar colony formation were observed in cells with silenced PTTG.
- Tumor incidence and growth were significantly decreased in nude mice injected with PTTG-silenced A2780 cells.
Conclusions:
- PTTG plays a crucial role in ovarian tumorigenesis.
- Down-regulation of PTTG significantly inhibits ovarian cancer cell growth and tumor development.
- PTTG represents a promising molecular target for developing novel ovarian cancer therapies.
Related Concept Videos
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
piRNA - Piwi-interacting RNAs